JP2004504348A5 - - Google Patents

Download PDF

Info

Publication number
JP2004504348A5
JP2004504348A5 JP2002513460A JP2002513460A JP2004504348A5 JP 2004504348 A5 JP2004504348 A5 JP 2004504348A5 JP 2002513460 A JP2002513460 A JP 2002513460A JP 2002513460 A JP2002513460 A JP 2002513460A JP 2004504348 A5 JP2004504348 A5 JP 2004504348A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
ring
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002513460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004504348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/022214 external-priority patent/WO2002007725A1/en
Publication of JP2004504348A publication Critical patent/JP2004504348A/ja
Publication of JP2004504348A5 publication Critical patent/JP2004504348A5/ja
Pending legal-status Critical Current

Links

JP2002513460A 2000-07-13 2001-07-13 線維症性疾患または他の適応症ｉｃを治療する方法 Pending JP2004504348A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21827300P 2000-07-13 2000-07-13
US25943100P 2000-12-29 2000-12-29
US25924201P 2001-01-02 2001-01-02
US29643501P 2001-06-06 2001-06-06
PCT/US2001/022214 WO2002007725A1 (en) 2000-07-13 2001-07-13 Method for treating fibrotic diseases or other indications ic

Publications (2)

Publication Number Publication Date
JP2004504348A JP2004504348A (ja) 2004-02-12
JP2004504348A5 true JP2004504348A5 (https=) 2009-04-09

Family

ID=27499106

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002513460A Pending JP2004504348A (ja) 2000-07-13 2001-07-13 線維症性疾患または他の適応症ｉｃを治療する方法
JP2002514116A Withdrawn JP2004504389A (ja) 2000-07-13 2001-07-13 シアノメチル置換化チアゾリウム及びイミダゾリウム、並びにタンパク質老化と関連する疾患の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2002514116A Withdrawn JP2004504389A (ja) 2000-07-13 2001-07-13 シアノメチル置換化チアゾリウム及びイミダゾリウム、並びにタンパク質老化と関連する疾患の治療

Country Status (10)

Country Link
US (8) US20020068729A1 (https=)
EP (3) EP1305024A4 (https=)
JP (2) JP2004504348A (https=)
AT (1) ATE304849T1 (https=)
AU (4) AU8055101A (https=)
CA (2) CA2415054A1 (https=)
DE (1) DE60113548T2 (https=)
ES (1) ES2251500T3 (https=)
MX (2) MXPA03000388A (https=)
WO (2) WO2002007725A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
NZ520573A (en) * 2000-02-23 2004-05-28 Alteon Inc Thiazolium compounds and treatments of disorders associated with protein aging
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
MXPA03000388A (es) * 2000-07-13 2003-09-25 Alteon Inc Metodo para tratar enfermedades fibroticas u otras indicaciones ic.
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
WO2002053161A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
JP2005519849A (ja) * 2001-06-15 2005-07-07 スリーエム イノベイティブ プロパティズ カンパニー 歯周病の治療用免疫応答調節剤
US7226928B2 (en) 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
US7144570B2 (en) * 2002-05-23 2006-12-05 Alteon, Inc. Sunscreen compositions and methods of use thereof
WO2003099241A2 (en) 2002-05-23 2003-12-04 Tony Maniscalco Sunscreen compositions and methods of use thereof
US20050014747A1 (en) * 2003-04-18 2005-01-20 Emily Reinhard Dihydrothiazine prodrugs of thiazolium agents
CA2540541C (en) 2003-10-03 2012-03-27 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
WO2005051317A2 (en) 2003-11-25 2005-06-09 3M Innovative Properties Company Substituted imidazo ring systems and methods
US20050191245A1 (en) * 2004-02-27 2005-09-01 Adams Christopher P. Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7764995B2 (en) * 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7729761B2 (en) * 2004-07-14 2010-06-01 Cardiac Pacemakers, Inc. Method and apparatus for controlled gene or protein delivery
US7828711B2 (en) * 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
WO2006063132A2 (en) 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7774057B2 (en) 2005-09-06 2010-08-10 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression for cardiac protection
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
CN101007789B (zh) * 2006-01-27 2014-08-20 北京摩力克科技有限公司 取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途
WO2009023207A1 (en) * 2007-08-13 2009-02-19 Synvista Therapeutics, Inc. Thiazolium compounds for treating gastrointestinal complications
WO2009051804A1 (en) * 2007-10-18 2009-04-23 Synvista Therapeutics, Inc. Thiazolium compounds for treating or preventing diseases associated with insulin resistance
CN101983057A (zh) * 2008-01-30 2011-03-02 新加坡科技研究局 用咪唑和咪唑啉化合物治疗纤维变性和癌症的方法
TNSN08110A1 (en) * 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
US20110028513A1 (en) * 2008-03-31 2011-02-03 Lang Zhuo Method for treating neurological disorders with imidazolium and imidazolinium compounds
CN104277011A (zh) * 2013-07-09 2015-01-14 中国人民解放军军事医学科学院毒物药物研究所 噻唑内盐类化合物及其治疗蛋白老化相关疾病的用途
US9622469B2 (en) 2013-10-03 2017-04-18 David Spiegel Crosslink breakers for preservation of biological substances
KR102467150B1 (ko) * 2016-05-06 2022-11-14 유니사이트 이브이 에이지 고혈당으로 인해 유발되는 섬유성 질환의 치료에 사용하기 위한 miRNA를 함유하는 약제학적 담체
CN106505185B (zh) * 2016-11-16 2019-11-15 南京师范大学 一种锑/氮掺杂碳复合物及其制备方法和应用
KR102952607B1 (ko) * 2019-12-20 2026-04-14 가천대학교 산학협력단 신규한 티아졸 유도체 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210096D0 (en) * 1992-05-11 1992-06-24 Fujisawa Pharmaceutical Co 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives and their preparation
NO315930B1 (no) * 1995-01-18 2003-11-17 Picower Inst For Medical Res T Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser
EP1327887A3 (en) * 1995-01-18 2008-12-10 Synvista Therapeutics, Inc. Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation end products
US5656261A (en) 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
US5850840A (en) * 1995-11-15 1998-12-22 Alteon Inc. Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
JPH107709A (ja) * 1996-06-24 1998-01-13 Toyo Ink Mfg Co Ltd 感エネルギー線活性剤組成物、それを用いた感応性組成物ならびに画像形成用組成物
US6391899B1 (en) * 1998-07-17 2002-05-21 North Shore—Long Island Jewish Research Institute Compounds and compositions for treating tissue ischemia
AU6384099A (en) * 1998-08-31 2000-03-21 Proteotech, Inc. Blended compositions for treatment of alzheimer's disease and other amyloidoses
US6121300A (en) * 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
JP2003533440A (ja) * 2000-04-03 2003-11-11 ブリストル−マイヤーズ スクイブ カンパニー 隔離心収縮期高血圧症を処置するバソペプチダーゼ抑制剤
MXPA03000388A (es) * 2000-07-13 2003-09-25 Alteon Inc Metodo para tratar enfermedades fibroticas u otras indicaciones ic.
US20030176426A1 (en) * 2000-07-13 2003-09-18 Alteon, Inc. Method for treating fibrotic diseases or other indications with imidazolium agents
WO2002053158A1 (en) * 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ib
US6853703B2 (en) * 2001-07-20 2005-02-08 Siemens Medical Solutions Usa, Inc. Automated delivery of treatment fields

Similar Documents

Publication Publication Date Title
JP2004504348A5 (https=)
US20030027820A1 (en) Method for treating fibrotic diseases or other indications V
NO20051036L (no) 3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander
JP2005539088A5 (https=)
JP2005537312A5 (https=)
WO1992009279A1 (fr) Derive de 2-arylthiazole et composition pharmaceutique contenant ce derive
JP2004506736A5 (https=)
BG63487B1 (bg) Използване на хетероциклени съединения
NO20055655L (no) Anvendelse av azetidinkarboksamidderivater i terapi
HU223530B1 (hu) 4-Alkil-imidazol-származékok
US6596745B2 (en) Method for treating fibrotic diseases with azolium chroman compounds
JP2007538031A5 (https=)
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
JP2004521150A5 (https=)
DK132188D0 (da) Anvendelse af tetrahydrobenz(c,d)indol-6-carboxamider som anxiolytika
KR880003920A (ko) 피리다지논 유도체
JP2004520329A5 (https=)
IL180171A0 (en) Novel 2-substituted d-homo-estra-1,3,5(10)-trienes as inhibitors of 17??- hydroxysteroid dehydrogenase type 1
JP2006501245A5 (https=)
JP2005513103A5 (https=)
RU2001116601A (ru) Новые производные пиримидина и способы их получения
JP2004505951A5 (https=)
FI955387A0 (fi) 4(p-fluorifenyyli)-3-((3,4-(metyleenioksi)fenoksi)metyyli)-piperidiinin N-p-halobentsoyylimetyylijohdannaiset
KR20050113627A (ko) 수용성 페닐피리다진 유도체 및 이를 함유하는 의약
KR20040039377A (ko) 수용성 페닐피리다진 유도체 및 이를 함유하는 의약